Loading the page…
Nasdaq 100
DXCM
DexCom, Inc., Health Care
$82.29
+2.95% on the day
Close of Fri, Oct 30, 2026
−1.4% over 3M
2026-07-312026-09-162026-10-30
Market cap$31.1B
Last close$82.29
Day move+2.95%
Nasdaq 100
DexCom, Inc., Health Care
$82.29
+2.95% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.3B | $1.2B | $1.2B | $1.0B | $1.1B | $994M |
| Gross margin | 63.4% | 62.9% | 62.9% | 60.5% | 59.5% | 56.9% | 58.9% | 59.7% |
| Operating margin | 24.3% | 21.4% | 25.6% | 20.1% | 18.4% | 12.9% | 17.0% | 15.3% |
| Net margin | 19.0% | 16.7% | 21.2% | 23.5% | 15.5% | 10.2% | 13.6% | 13.5% |
| EPS, diluted | $0.64 | $0.51 | $0.67 | $0.70 | $0.45 | $0.27 | $0.37 | $0.34 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | DXCM | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 3.2% | 58% |
| Book yield (book value ÷ price) | 8.4% | 40% |
| Free cash flow yield | 3.5% | 61% |
| Buyback yield | 1.6% | 69% |
| Revenue growth, a year | 15.6% | 64% |
| EPS growth, a year | 47.2% | 78% |
| Return on equity | 38.1% | 76% |
| Return on assets | 15.5% | 67% |
| Net margin | 20.1% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 53% |
| Liabilities ÷ assets | 59.4% | 59% |
|---|
| Past year, skipping last month | 26.5% | 65% |
|---|
| Past 6 months, skipping last month | 40.6% | 88% |
|---|
| Volatility, a year's worth | 30.6% | 32% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
From Yahoo Finance, dexcom.com
Picked by YouTube search, not by us. Someone else's view, not advice.
DexCom (DXCM) Stock Looks Below Fair Value on Cash FlowSimply Wall St., 13h agoDexCom (DXCM) Brings Its 15 Day Glucose Monitor To CanadaSimply Wall St., 17h ago
Dexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes OffInvestor's Business Daily, Oct 30
DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC SaysMT Newswires, Oct 30
Dexcom (DXCM) Q3 2026 Earnings Call TranscriptMotley Fool, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
DexCom (DXCM) Stock Looks Below Fair Value on Cash FlowSimply Wall St., 13h agoDexCom (DXCM) Brings Its 15 Day Glucose Monitor To CanadaSimply Wall St., 17h agoDexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes OffInvestor's Business Daily, Oct 30DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC SaysMT Newswires, Oct 30Dexcom (DXCM) Q3 2026 Earnings Call TranscriptMotley Fool, Oct 30
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseZacks, Oct 30UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy RatingMT Newswires, Oct 30
DexCom, Inc. Q3 2026 Earnings Call SummaryMoby, Oct 30Barclays Adjusts Price Target on DexCom to $120 From $115MT Newswires, Oct 30Raymond James Adjusts Price Target on DexCom to $97 From $94MT Newswires, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | Stern SadieEVP Chief People & Culture Off | Sold on the market10b5-1 plan | −2,565 | $78.62 | $202K | Form 4 ↗ |
| Oct 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Sold on the market10b5-1 plan | −1,700 | $85.48 | $145K | Form 4 ↗ |
| Sep 28, 2026 | Stern SadieEVP Chief People & Culture Off | Sold on the market10b5-1 plan | −2,565 | $86.15 | $221K | Form 4 ↗ |
| Sep 15, 2026 | Augustinos NicholasDirector | Sold on the market10b5-1 plan | −6,539 | $84.04 | $550K | Form 4 ↗ |
| Sep 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Sold on the market10b5-1 plan | −1,700 | $84.04 | $143K | Form 4 ↗ |
| Sep 14, 2026 | Augustinos NicholasDirector | Sold on the market10b5-1 plan | −1,550 | $84.02 | $130K | Form 4 ↗ |
| Sep 10, 2026 | Sylvain Jereme MEVP, Chief Financal Officer | Sold on the market10b5-1 plan | −3,638 | $83.27 | $303K | Form 4 ↗ |
| Sep 10, 2026 | Boehnlein Glenn SDirector | Award | +5,841 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Stern SadieEVP Chief People & Culture Off | Sold on the market10b5-1 plan | −2,565 | $88.37 | $227K | Form 4 ↗ |
| Aug 22, 2026 | Leach Jacob StevenPresident, CEO, and Director | Tax withholding | −1,451 | $92.34 | $134K | Form 4 ↗ |
| Aug 22, 2026 | Sylvain Jereme MEVP, Chief Financal Officer | Tax withholding | −1,451 | $92.34 | $134K | Form 4 ↗ |
| Aug 22, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Tax withholding | −1,451 | $92.34 | $134K | Form 4 ↗ |
| Aug 22, 2026 | Stern SadieEVP Chief People & Culture Off | Tax withholding | −1,451 | $92.34 | $134K | Form 4 ↗ |
| Aug 20, 2026 | Sayer Kevin RExecutive Chair, Director | Sold on the market10b5-1 plan | −26,756 | $90.01average | $2.4M | Form 4 ↗ |
| Aug 14, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Sold on the market10b5-1 plan | −1,700 | $91.93 | $156K | Form 4 ↗ |
| Aug 12, 2026 | Augustinos NicholasDirector | Gift | −1,075 | — | — | Form 4 ↗ |
| Aug 12, 2026 | Heller Bridgette PDirector | Sold on the market10b5-1 plan | −1,012 | $88.29 | $89.3K | Form 4 ↗ |
| Aug 3, 2026 | Foletta Mark GDirector | Sold on the market10b5-1 plan | −2,000 | $85.32 | $171K | Form 4 ↗ |
| Jul 31, 2026 | Foletta Mark GDirector | Sold on the market10b5-1 plan | −2,000 | $80.00 | $160K | Form 4 ↗ |
| Jul 20, 2026 | Sayer Kevin RExecutive Chair, Director | Sold on the market10b5-1 plan | −26,756 | $76.32 | $2.0M | Form 4 ↗ |
| Jul 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Sold on the market10b5-1 plan | −1,700 | $74.42 | $127K | Form 4 ↗ |
| Jul 6, 2026 | Sayer Kevin RExecutive Chair, Director | Sold on the market10b5-1 plan | −26,756 | $72.00 | $1.9M | Form 4 ↗ |
| Jun 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Sold on the market10b5-1 plan | −1,700 | $75.55 | $128K | Form 4 ↗ |
| Jun 15, 2026 | Foletta Mark GDirector | Sold on the market10b5-1 plan | −4,000 | $74.13average | $297K | Form 4 ↗ |
| Jun 4, 2026 | Coleman JonEVP, Chief Commercial Officer | Sold on the market10b5-1 plan | −4,911 | $74.13 | $364K | Form 4 ↗ |
| Jun 3, 2026 | Coleman JonEVP, Chief Commercial Officer | Sold on the market10b5-1 plan | −4,912 | $73.00 | $359K | Form 4 ↗ |
| May 28, 2026 | Altman Steven RDirector | Award | +5,565 | — | — | Form 4 ↗ |
| May 28, 2026 | Malady KyleDirector | Award | +5,575 | — | — | Form 4 ↗ |
| May 28, 2026 | Augustinos NicholasDirector | Award | +5,575 | — | — | Form 4 ↗ |
| May 28, 2026 | Foletta Mark GDirector | Award | +6,331 | — | — | Form 4 ↗ |
| May 28, 2026 | Heller Bridgette PDirector | Award | +5,575 | — | — | Form 4 ↗ |
| May 28, 2026 | Osterloh Albert Frederick IVDirector | Award | +1,630 | — | — | Form 4 ↗ |
| May 28, 2026 | Driscoll RimmaDirector | Award | +5,605 | — | — | Form 4 ↗ |
| May 28, 2026 | Ashley Euan A.Director | Award | +5,565 | — | — | Form 4 ↗ |
| May 28, 2026 | Collins Richard AlexanderDirector | Award | +5,605 | — | — | Form 4 ↗ |
| May 28, 2026 | Gala Renee DDirector | Award | +5,605 | — | — | Form 4 ↗ |
| May 22, 2026 | Leach Jacob StevenPresident, CEO, and Director | Tax withholding | −1,451 | $71.90 | $104K | Form 4 ↗ |
| May 22, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Tax withholding | −1,451 | $71.90 | $104K | Form 4 ↗ |
| May 22, 2026 | Sylvain Jereme MEVP, Chief Financal Officer | Tax withholding | −1,451 | $71.90 | $104K | Form 4 ↗ |
| May 22, 2026 | Stern SadieEVP Chief People & Culture Off | Tax withholding | −1,451 | $71.90 | $104K | Form 4 ↗ |
| May 22, 2026 | Coleman JonEVP, Chief Commercial Officer | Tax withholding | −7,362 | $71.90 | $529K | Form 4 ↗ |
| May 21, 2026 | Sayer Kevin RExecutive Chair, Director | Sold on the market10b5-1 plan | −26,759 | $72.00 | $1.9M | Form 4 ↗ |
| May 15, 2026 | Brown Michael JonEVP, Chief Legal Officer | Sold on the market10b5-1 plan | −1,700 | $59.91 | $102K | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.